Metagenomi Therapeutics opened higher at $0.83, compared with its previous close of $0.76. In the last trading session, the stock traded between $0.70 and $0.83. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Metagenomi Therapeutics is now worth
$ 6.96
Resulting in a loss of
$ 93.04 (93.04%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-5.06%)
Day High
$0.83
Day Low
$0.70
Day Open
$0.83
Prev Close
$0.76
Volume
1,71,505
1W Return
-10.36%
1M Return
-29.95%
3M Return
-41.15%
6M Return
-46.81%
1Y Return
-67.36%
Fundamentals
Market Cap ($ Mn)
27
PE Ratio
-
PB Ratio
0.40
PEG Ratio
-
ROE
-44.81%
ROCE
-40.55%
EPS (TTM)
$-0.56
Investment Returns
1 Week
-10.36%
1 Month
-29.95%
3 Months
-41.15%
6 Months
-46.81%
9 Months
-52.76%
Financials
Quarterly
All values in $ Mn
8.5
Jun 25
8.7
Sep 25
3.9
Dec 25
1.2
Mar 26
-0.3
Jun 26
2.2
Sep 26
Updates
11Nov
Metagenomi gets FDA clearance for MGX-001 hemophilia A trial
FDA cleared the IND application for MGX-001. MGX-001 targets hemophilia A treatment. Company reported Q3FY26 financial results.
2 days ago
4Nov
Metagenomi to present MGX-001 preclinical data at ASH annual meeting
Metagenomi Therapeutics announces oral presentation on MGX-001. Presentation scheduled for the 68th ASH Annual Meeting in New Orleans. Dr. Alan Brooks, SVP of Research, will deliver the findings.
8 days ago
25Aug
Halper Sadeh probes Metagenomi Therapeutics for fiduciary breaches
Halper Sadeh LLC investigates Metagenomi Therapeutics insiders for fiduciary breaches. Long-term shareholders may seek governance reforms or financial relief. Firm offers services on a contingent fee basis with no upfront costs.
2mo ago
11Aug
Metagenomi Therapeutics reports $27.5M loss in Q2 2026
Metagenomi Therapeutics posted a widened Q2 2026 net loss of $27.482 million and EPS of $(0.73), missing analyst expectations. Collaboration revenue fell sharply to $(0.257) million from $8.513 million in Q2 2025. Despite the losses, the company holds $120.664 million in cash, providing a runway through 4Q 2027. Key operational progress includes Top Poster Awards for MGX-001 at ISTH 2026 and a timeline for IND submission in 4Q 2026.
3mo ago
7Jul
Chardan Capital maintains Buy on Metagenomi Therapeutics, cuts target to $5
Chardan Capital analyst Keay Nakae maintained a Buy rating on Metagenomi Therapeutics while lowering the price target to $5 from $7.
